Close Menu

NEW YORK – Tel Aviv-based biopharmaceutical company VBL Therapeutics today announced plans to extend its ongoing Phase III OVAL trial to Japan through a licensing agreement with NanoCarrier. The global, randomized OVAL trial is evaluating VBL's drug, VB-111, in patients with platinum-resistant ovarian cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.